Comparison of Early Results of Stand-alone XEN Gel Stent Implantation to Treat Pseudoexfoliative Glaucoma and Primary Open-angle Glaucoma

Abstract

Purpose: To compare the postoperative outcomes of stand-alone XEN45® Gel Stent implantation in patients with pseudoexfoliative glaucoma (PEXG) and primary open-angle glaucoma (POAG). Materials and Methods: This study included 69 eyes of 46 patients with POAG and 26 eyes of 17 patients with PEXG who had undergone XEN45® stent implantation. The inter- and intra-group changes in mean intraocular pressure (IOP), glaucoma medication requirements, needling rate, incidence of adverse effects, and success rate were analyzed. Results: There was no signifi cant intergroup difference in the mean IOP (p=0.326) or number of antiglaucoma medications (p=0.450) preoperatively. Both groups showed a signifi cant decrease in IOP and antiglaucoma medication usage at all postoperative time points, relative to the preoperative values. However, there was no signifi cant intergroup difference in the mean IOP or number of medications at any postoperative endpoint. In the POAG group (n=37) the mean preoperative IOP was 23.10±3.90 mmHg, with an average of 3.32±0.47 medications being used; these values decreased to 13.27±1.74 mmHg (42.5% decrease) and 0.70±1.24 (78.9% decrease) after 12 months of postoperative followup, respectively. Similarly, the mean IOP and number of medications used in the PEXG group (n=11) decreased from 22.63±3.23 mmHg and 3.18±0.60 preoperatively to 13.00±2.61 mmHg (42.5% decrease) and 1.27±1.49 (60% decrease) at 12 months postoperatively, respectively. Conclusion: In our study, stand-alone XEN® Gel Stent implantation produced no signifi cant difference in change in IOP or antiglaucoma medication usage between overall patients with POAG and PEXG, However, complete success rate was lower in the PEXG group.